Tags : Catalent

PharmaShots Weekly Snapshot (Jun 15-19, 2020)

 1.  Ultragenyx and Kyowa Kirin’s Crysvita (burosumab) Receive the US FDA’s Approval for the Treatment of Tumor-Induced Osteomalacia  Published: Jun 19, 2020 | Tags: Ultragenyx, Kyowa Kirin, Crysvita, burosumab, Receives, US, FDA, Approval, Treatment, Tumor-Induced Osteomalacia 2.  Pfizer and Sangamo’s Giroctocogene Fitelparvovec (SB-525) Demonstrate Positive Effect in P-I/II Alta Study for Hemophilia A Published: Jun 18, 2020 […]Read More

AstraZeneca Signs an Agreement with Catalent to Manufacture AZD1222 for

Shots: Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Italy and prepare for large-scale commercial supply of AZD1222 The agreement ramps up the production of AZD1222 and will prepare the facility to enable round-the-clock manufacturing schedules and supply hundreds of millions of doses of AZD1222 from Aug’2020 […]Read More

Johnson & Johnson Signs a Manufacturing Agreement with the Catalent

Shots: The alliance includes joint investment and tech transfer to accelerate rapid scale-up of segregated manufacturing capacity over the coming months for supporting J&J’s vaccine candidates Catalent will accelerate the availability of manufacturing capacity and prepare for large-scale commercial manufacturing at its facility in Bloomington and plans to hire ~300 additional employees for the program […]Read More

Bristol-Myers Squibb to Sell its Manufacturing Facility to Catalent in

Shots: Catalent to purchase BMS’ oral solid, biologics, and sterile product manufacturing and packaging facility and will continue to manufacture BMS’s current product portfolio at the site, providing facilities in Europe, Belgium & NA Bristol-Myers Squibb will maintain its strategic presence in Italy with the ongoing development and commercialization of new therapies. The transaction is […]Read More